Patents by Inventor Andrew C. Braisted
Andrew C. Braisted has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20140179542Abstract: The present invention is directed to novel methods for rapidly and unambiguously identifying small organic molecule ligands for binding to biological target molecules. Small organic molecule ligands identified according to the methods of the present invention may find use, for example, as novel therapeutic drug lead compounds, enzyme inhibitors, labeling compounds, diagnostic reagents, affinity reagents for protein purification, and the like. Also presented are novel methods for identifying high affinity binding ligands for a biological target molecule of interest, wherein those methods comprise linking two or more small organic molecule ligands previously identified as being capable of binding to the biological target molecule of interest. Biological target molecules include, for example, polypeptides, nucleic acids, carbohydrates, nucleoproteins, glycoproteins, glycolipids and lipoproteins.Type: ApplicationFiled: July 11, 2013Publication date: June 26, 2014Inventors: Jim Wells, Dan Erlanson, Andrew C. Braisted
-
Publication number: 20120077711Abstract: The present invention provides compounds and libraries of compounds having formula (I): wherein L, n, S and A are defined generally and subsets herein. These compounds and libraries of compounds are useful generally in the drug discovery process.Type: ApplicationFiled: May 26, 2011Publication date: March 29, 2012Applicant: SUNESIS PHARMACEUTICALS, INC.Inventors: Andrew C. Braisted, Daniel A. Erlanson, Jeffrey W. Jacobs
-
Publication number: 20100022399Abstract: The present invention is directed to novel methods for rapidly and unambiguously identifying small organic molecule ligands for binding to biological target molecules. Small organic molecule ligands identified according to the methods of the present invention may find use, for example, as novel therapeutic drug lead compounds, enzyme inhibitors, labeling compounds, diagnostic reagents, affinity reagents for protein purification, and the like. Also presented are novel methods for identifying high affinity binding ligands for a biological target molecule of interest, wherein those methods comprise linking two or more small organic molecule ligands previously identified as being capable of binding to the biological target molecule of interest. Biological target molecules include, for example, polypeptides, nucleic acids, carbohydrates, nucleoproteins, glycoproteins, glycolipids and lipoproteins.Type: ApplicationFiled: October 1, 2009Publication date: January 28, 2010Inventors: Jim Wells, Dan Erlanson, Andrew C. Braisted
-
Publication number: 20080261831Abstract: The invention relates to variants of Target Biological Molecules (TBMs), such as proteins, peptides and other amino acid sequences that are modified to include cysteine residues at predetermined positions within the TBM. The position of amino acid residues within the TBM that are modified to be cysteine residues is selected for its proximity to ligand binding sites within the TBM. Once an amino acid residue, or the DNA encoding the residue, is modified to cysteine, the TBM linked to potential binding ligands by forming a covalent bond through the cysteine thiol (—SH) reactive group of the variant.Type: ApplicationFiled: December 1, 2006Publication date: October 23, 2008Inventors: Jim Wells, Dan Erlanson, Andrew C. Braisted
-
Patent number: 6998233Abstract: The present invention provides novel methods for ligand discovery. The inventive methods rely on a process termed “tethering” where potential ligands are covalently bonded or “tethered” to a target and subsequently identified.Type: GrantFiled: April 10, 2002Date of Patent: February 14, 2006Assignee: Sunesis Pharmaceuticals, Inc.Inventors: Jim Wells, Dan Erlanson, Andrew C. Braisted
-
Patent number: 6919178Abstract: The invention concerns a method for rapid identification and characterization of binding partners for a target molecule, and for providing binding partners with improved binding affinity. More specifically, the invention concerns an improved tethering method for the rapid identification of at least two binding partners that bind near one another to a target molecule.Type: GrantFiled: November 21, 2001Date of Patent: July 19, 2005Assignee: Sunesis Pharmaceuticals, Inc.Inventors: Daniel A. Erlanson, Andrew C. Braisted, Robert McDowell, John Prescott
-
Patent number: 6811966Abstract: The present invention is directed to novel methods for rapidly and unambiguously identifying small organic molecule ligands for binding to biological target molecules. Small organic molecule ligands identified according to the methods of the present invention may find use, for example, as novel therapeutic drug lead compounds, enzyme inhibitors, labeling compounds, diagnostic reagents, affinity reagents for protein purification, and the like. Also presented are novel methods for identifying high affinity binding ligands for a biological target molecule of interest, wherein those methods comprise linking two or more small organic molecule ligands previously identified as being capable of binding to the biological target molecule of interest. Biological target molecules include, for example, polypeptides, nucleic acids, carbohydrates, nucleoproteins, glycoproteins, glycolipids and lipoproteins.Type: GrantFiled: January 11, 2002Date of Patent: November 2, 2004Assignee: Sunesis Pharmaceuticals, Inc.Inventors: Jim Wells, Dan Erlanson, Andrew C. Braisted
-
Publication number: 20040043426Abstract: The present invention provides novel methods for ligand discovery. The inventive methods rely on a process termed “tethering” where potential ligands are covalently bonded or “tethered” to a target and subsequently identified.Type: ApplicationFiled: June 18, 2003Publication date: March 4, 2004Inventors: Jim Wells, Dan Erlanson, Andrew C. Braisted
-
Publication number: 20030104471Abstract: The present invention is directed to novel methods for rapidly and unambiguously identifying small organic molecule ligands for binding to biological target molecules. Small organic molecule ligands identified according to the methods of the present invention may find use, for example, as novel therapeutic drug lead compounds, enzyme inhibitors, labeling compounds, diagnostic reagents, affinity reagents for protein purification, and the like. Also presented are novel methods for identifying high affinity binding ligands for a biological target molecule of interest, wherein those methods comprise linking two or more small organic molecule ligands previously identified as being capable of binding to the biological target molecule of interest. Biological target molecules include, for example, polypeptides, nucleic acids, carbohydrates, nucleoproteins, glycoproteins, glycolipids and lipoproteins.Type: ApplicationFiled: January 11, 2002Publication date: June 5, 2003Inventors: Jim Wells, Dan Erlanson, Andrew C. Braisted
-
Publication number: 20030013125Abstract: The present invention provides compounds and libraries of compounds having formula (I): 1Type: ApplicationFiled: May 10, 2002Publication date: January 16, 2003Inventors: Andrew C. Braisted, Daniel A. Erlanson, Jeffrey W. Jacobs
-
Publication number: 20020155505Abstract: The present invention provides novel methods for ligand discovery. The inventive methods rely on a process termed “tethering” where potential ligands are covalently bonded or “tethered” to a target and subsequently identified.Type: ApplicationFiled: April 10, 2002Publication date: October 24, 2002Inventors: Jim Wells, Dan Erlanson, Andrew C. Braisted
-
Publication number: 20020151473Abstract: Provided are cyclized peptides with a constrained region(s) having an &agr;-helical conformation. Constrained helical peptides having amino acid sequences from HIV gp41 are provided, as is their use in preparing antibodies that prevent viral membrane fusion. Also provided are methods for making such cyclized peptides.Type: ApplicationFiled: May 15, 2001Publication date: October 17, 2002Inventors: Andrew C. Braisted, J. Kevin Judice, Robert S. McDowell, J. Christopher Phelan, Melissa A. Starovasnik, James A. Wells
-
Publication number: 20020150947Abstract: The invention concerns a method for rapid identification and characterization of binding partners for a target molecule, and for providing binding partners with improved binding affinity. More specifically, the invention concerns an improved tethering method for the rapid identification of at least two binding partners that bind near one another to a target molecule.Type: ApplicationFiled: November 21, 2001Publication date: October 17, 2002Inventors: Daniel A. Erlanson, Andrew C. Braisted, Robert McDowell, John Prescott
-
Publication number: 20020081621Abstract: The present invention is directed to novel methods for rapidly and unambiguously identifying small organic molecule ligands for binding to biological target molecules. Small organic molecule ligands identified according to the methods of the present invention may find use, for example, as novel therapeutic drug lead compounds, enzyme inhibitors, labeling compounds, diagnostic reagents, affinity reagents for protein purification, and the like. Also presented are novel methods for identifying high affinity binding ligands for a biological target molecule of interest, wherein those methods comprise linking two or more small organic molecule ligands previously identified as being capable of binding to the biological target molecule of interest. Biological target molecules include, for example, polypeptides, nucleic acids, carbohydrates, nucleoproteins, glycoproteins, glycolipids and lipoproteins.Type: ApplicationFiled: February 20, 2002Publication date: June 27, 2002Inventors: Jim Wells, Dan Erlanson, Andrew C. Braisted
-
Publication number: 20020022233Abstract: The present invention is directed to novel methods for rapidly and unambiguously identifying small organic molecule ligands for binding to biological target molecules. Small organic molecule ligands identified according to the methods of the present invention may find use, for example, as novel therapeutic drug lead compounds, enzyme inhibitors, labeling compounds, diagnostic reagents, affinity reagents for protein purification, and the like. Also presented are novel methods for identifying high affinity binding ligands for a biological target molecule of interest, wherein those methods comprise linking two or more small organic molecule ligands previously identified as being capable of binding to the biological target molecule of interest. Biological target molecules include, for example, polypeptides, nucleic acids, carbohydrates, nucleoproteins, glycoproteins, glycolipids and lipoproteins.Type: ApplicationFiled: October 17, 2001Publication date: February 21, 2002Inventors: Jim Wells, Dan Erlanson, Andrew C. Braisted
-
Patent number: 6335155Abstract: The present invention is directed to novel methods for rapidly and unambiguously identifying small organic molecule ligands for binding to biological target molecules. Small organic molecule ligands identified according to the methods of the present invention may find use, for example, as novel therapeutic drug lead compounds, enzyme inhibitors, labeling compounds, diagnostic reagents, affinity reagents for protein purification, and the like. Also presented are novel methods for identifying high affinity binding ligands for a biological target molecule of interest, wherein those methods comprise linking two or more small organic molecule ligands previously identified as being capable of binding to the biological target molecule of interest. Biological target molecules include, for example, polypeptides, nucleic acids, carbohydrates, nucleoproteins, glycoproteins, glycolipids and lipoproteins.Type: GrantFiled: June 26, 1998Date of Patent: January 1, 2002Assignee: Sunesis Pharmaceuticals, Inc.Inventors: Jim Wells, Dan Erlanson, Andrew C. Braisted
-
Patent number: 6271198Abstract: Provided are cyclized peptides with a constrained region(s) having an &agr;-helical conformation. Constrained helical peptides having amino acid sequences from HIV gp41 are provided, as is their use in preparing antibodies that prevent viral membrane fusion. Also provided are methods for making such cyclized peptides.Type: GrantFiled: November 5, 1997Date of Patent: August 7, 2001Assignee: Genentech, Inc.Inventors: Andrew C. Braisted, J. Kevin Judice, Robert S. McDowell, J. Christopher Phelan, Melissa A. Starovasnik, James A. Wells
-
Patent number: 6197927Abstract: Z domain variants of staphylococcal protein A have significantly reduced size but possess IgG-binding affinity equivalent to the wild type Z domain. These Z domain variants are suitable for use in affinity chromatography purification of proteins and in the treatment of staphylococcic diseases.Type: GrantFiled: March 6, 1998Date of Patent: March 6, 2001Assignee: Genentech Inc.Inventors: Andrew C. Braisted, Melissa A. Starovasnik, James A. Wells
-
Patent number: 6013763Abstract: Z domain variants of staphylococcal protein A have significantly reduced size but possess IgG-binding affinity equivalent to the wild type Z domain. These Z domain variants are suitable for use in affinity chromatography purification of proteins and in the treatment of staphylococcic diseases.Type: GrantFiled: June 4, 1996Date of Patent: January 11, 2000Assignee: Genentech, Inc.Inventors: Andrew C. Braisted, Melissa A. Starovasnik, James A. Wells
-
Patent number: 5081118Abstract: A series of novel oxyethyl derivatives of certain selected enolic oxicam compounds are disclosed, including certain novel oxyethyl derivatives of 4-hydroxy-2-methyl-N-(2-pyridinyl)-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide (piroxicam). These particular compounds are useful in therapy as prodrug forms of the known anti-inflammatory and analgesic oxicams. Said oxyethyl derivatives of enoic oxicam compounds like piroxicam are of the formulae: ##STR1## wherein R.sub.1 is hydrogen, methyl, fluorine or chlorine, and R.sub.2 is hydrogen or --COOR.sub.3 wherein R.sub.3 is alkyl having from one to eight carbon atoms.Type: GrantFiled: April 26, 1990Date of Patent: January 14, 1992Assignee: Pfizer Inc.Inventors: Andrew C. Braisted, Philip D. Hammen